)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Alligator Bioscience (ATORX) investor relations material
Alligator Bioscience Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary23 Oct, 2025
Executive summary
30-month follow-up data from the phase II study in metastatic pancreatic cancer confirmed long-term survival benefit of mitazalimab, reinforcing its transformative potential and Phase 3 readiness.
Multiple investigator-initiated phase I/II studies for mitazalimab are being launched in new indications, including oral premalignancies and biliary tract cancer.
SEK 28.1 million was raised via 91.7% exercise of TO 13 warrants and a SEK 120 million rights issue was announced, with 65% secured, providing a 6–9 month runway into 2026 for Phase 3 preparations.
Partnering discussions for mitazalimab and other pipeline assets are progressing, with optimism for future deals and expanded clinical development.
Advanced pipeline with new clinical data, manufacturing readiness, and expanded investigator-initiated trials.
Financial highlights
Q3 operating costs were SEK 17 million, reflecting reduced expenses as the phase II trial winds down.
Net sales for Q3 2025 were SEK 0.47 million, down from SEK 1.4 million in Q3 2024.
Operating loss for Q3 2025 was SEK -17.3 million, a significant improvement from SEK -62.0 million in Q3 2024.
Cash and cash equivalents at period end were SEK 25.1 million, compared to SEK 47.8 million a year earlier.
Earnings per share after dilution for Q3 2025 was SEK -0.34 (Q3 2024: SEK -87.74, adjusted for reverse split).
Outlook and guidance
Rights issue and loan renegotiation expected to secure 6–9 months of funding into 2026, supporting Phase 3 trial preparations and partnership discussions.
Several phase II investigator-initiated trials for mitazalimab are scheduled to start in Q4 2025 and Q2 2026.
If the rights issue is fully subscribed, additional value-generating activities may be initiated.
Continued focus on securing licensing and partnership agreements to support future financing.
Focus remains on initiating Phase 3 trial for mitazalimab with a partner and expanding the pipeline's impact.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Alligator Bioscience earnings date
Q4 202512 Feb, 2026
Next Alligator Bioscience earnings date
Q4 202512 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage